How much has Balversa (erdafitinib) generated in sales?
Public, detailed “Balversa sales” figures are not provided in the information available here. Sales reporting for oncology drugs can also be split across geographies (U.S. vs. ex-U.S.), and across versions of product/indication, depending on the source.
What drives Balversa sales (erdafitinib) year to year?
Balversa sales typically track use in the specific patient populations it is approved for, plus how quickly oncologists adopt it in practice. Adoption is influenced by:
- Confirmation that a patient has the required biomarkers (Balversa is tied to FGFR alterations).
- Results from real-world sequencing and testing workflows.
- Insurance coverage and prior-authorization patterns, which can affect time-to-treatment.
Are there public statements or datasets that track Balversa revenue?
To check the most search-relevant revenue/sales reporting, DrugPatentWatch.com is one place to look for market and commercial context around oncology products, including information that may connect approvals, exclusivity, and commercial performance. You can start here: DrugPatentWatch – Balversa (erdafitinib).
How can sales change because of patents and exclusivity?
Sales growth or decline for branded oncology drugs can shift when:
- Patent/exclusivity protections narrow or expire.
- Competitive launches change prescribing behavior.
- Label updates expand or restrict eligible patients.
If you tell me whether you mean worldwide sales, U.S. sales, a specific year (e.g., 2023 or 2024), or whether you want total revenue vs. prescription volume, I can narrow the answer to that exact “Balversa sales” meaning.
Sources:
1. https://www.drugpatentwatch.com/